Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAD044 dose-ranging placebo-controlled study in hereditary hemorrhagic telangiectasia
NL-OMON53637Completed
- Sponsor
- Vaderis Therapeutics AG
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of engasertib in hereditary hemorrhagic telangiectasia (HHT) (4 arms), sponsored by Vaderis Therapeutics AG. Primary endpoints: Safety and tolerability and Long-term safety and tolerability. Started Jan 2022; status: completed.
02
Drugs
engasertib
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NL-OMON53637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53637.